Qianqian Yi,
Zhiyu Wu,
Junhua Dong 
,
Ningning Zhang,
Qiuyue Li,
Na Gao
For correspondence:- Junhua Dong Email: 1042925091@qq.com Tel:+867176222838
Accepted: 17 June 2021 Published: 30 July 2021
Citation: Yi Q, Wu Z, Dong J, Zhang N, Li Q, Gao N. Comparison of effectiveness of continuous subcutaneous insulin infusion with daily insulin injection in a Chinese population of Type I diabetic patients. Trop J Pharm Res 2021; 20(7):1517-1522 doi: 10.4314/tjpr.v20i7.27
© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To compare the clinical effectiveness of continuous subcutaneous insulin infusion therapy with that of multiple-dose insulin therapy in type 1 diabetic patients.
Methods: A total of 1000 type 1 diabetic patients were assigned to two groups, with 500 patients per group. Patients in group I were treated with continuous subcutaneous infusion of insulin (CSII), while those in group II received multiple daily doses of insulin injection. Body mass index (BMI), insulin dose, HbA1c levels, and frequencies of hypoglycemia and diabetic-ketoacidosis (DKA) were determined in each patient at baseline, and at 4-week intervals for 4 years.
Results: The HbA1c levels at baseline and at the end of 4th year in group I were 8.9 ± 1.1 and 8.2 ± 1.5 %, respectively, relative to corresponding values of 8.6 ± 1.2 and 9.1 ± 1.1 %, respectively in group II. The results revealed significant difference in HbA1c between the two groups (p < 0.05). After 4 years of therapy, insulin requirement was markedly higher in group II than at baseline (0.8 ± 0.1 vs 0.9 ± 0.2, p < 0.05) IU/kg/day. However, insulin requirement in group I decreased after 4 years, relative to that at baseline (0.65 ± 0.2 vs 0.8 ± 0.1 IU/kg/day; p < 0.05).
Conclusion: CSII therapy seems to be an effective and safe gold standard method for managing type I diabetes mellitus patients.
Archives
News Updates
Fulltext in PDF